Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Stock-based Compensation

v3.24.1.1.u2
Note 12 - Stock-based Compensation
3 Months Ended
Mar. 31, 2024
Notes to Financial Statements  
Stock-based compensation
12.
Stock‑based compensation:

All references in this report to historical Common Share prices, numbers of Common Shares, and earnings per share calculations have been presented to reflect the effect of the Reverse Stock Split.

a.
Stock option plan and employee stock purchase plan

Effective June 1, 2021, the Company adopted a new stock incentive plan (“New Incentive Plan”) and an employee stock purchase plan (“ESPP”).

The New Incentive Plan authorizes the Board of Directors to administer the New Incentive Plan to provide equity-based compensation in the form of stock options, stock appreciation rights, restricted stock, restricted stock units and dividend equivalents.

The Corporation currently maintains its existing Share Option Plan and 2015 Stock Incentive Plan (2015 SIP). Effective June 1, 2021 no further grants will be made under the Share Option Plan or 2015 SIP, though existing grants under the Share Option Plan will remain in effect in accordance with their terms.

The aggregate number of our Common Shares, no par value, that may be issued under all awards under the New Incentive Plan is (i) 691,400, plus (ii) any of our Common Shares subject to any outstanding award under our prior plans that, after June 1, 2021, are not purchased or are forfeited or reacquired by us, or otherwise not delivered to the participant due to termination, cancellation or cash settlement of such award subject to the share counting provisions of the New Incentive Plan.

Under both the Share Option Plan and the New Incentive Plan, the exercise price of each option equals the closing trading price of the Company’s stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day

of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no greater than ten years from the date of grant.

The Company uses the fair value-based method of accounting for employee awards granted under both plans. The Company calculates the fair value of each stock option grant using the Black-Scholes option pricing model at the grant date. The stock-based compensation cost of the options is recognized as stock-based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest.

The ESPP, which is administered by the Board of Directors, allows eligible employees of the Company to purchase Common Shares through accumulated payroll deductions up to a maximum 15% of eligible compensation. The ESPP is implemented in consecutive offering periods with a new offering period commencing on the first trading day on or after February 1 and August 1 each year, or on such other date as the Board of Directors will determine and continuing thereafter until terminated in accordance with the Plan. Unless the Board of Directors provides otherwise, the purchase price will be equal to eighty-five percent (85%) of the fair market value of a Common Share on the offering date or the exercise date, whichever is lower.

The maximum number of Common Shares which will be available for sale under the ESPP is 113,333 Common Shares. There were 10,891 and 1,438 Common Shares issued under the ESPP during the three months ended March 31, 2024 and March 31, 2023, respectively.

Stock option transactions for the three months ended March 31, 2024 and March 31, 2023 are summarized as follows:

 

 

 

 

 

 

Three months ended
March 31, 2024

 

 

 

 

 

 

Options (in thousands)

 

 

Weighted average
exercise price

 

 

Weighted average remaining contractual life
(years)

 

Outstanding, beginning of period

 

 

1,184

 

 

$

44.78

 

 

 

 

Granted

 

 

408

 

 

 

2.00

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(87

)

 

 

11.46

 

 

 

 

Outstanding, end of the period

 

 

1,505

 

 

$

34.98

 

 

 

7.04

 

Exercisable, end of the period

 

 

896

 

 

$

53.41

 

 

 

5.56

 

Vested and expected to vest, end of period

 

 

1,340

 

 

$

36.76

 

 

 

7.03

 

 

 

 

 

 

 

 

Three months ended
March 31, 2023

 

 

 

 

 

 

Options (in thousands)

 

 

Weighted average
exercise price

 

 

Weighted average remaining
contractual
life (years)

 

Outstanding, beginning of period

 

 

1,100

 

 

$

52.20

 

 

 

 

Granted

 

 

215

 

 

 

8.40

 

 

 

 

Exercised

 

 

 

 

 

0.00

 

 

 

 

Forfeited

 

 

(59

)

 

 

18.00

 

 

 

 

Outstanding, end of the period

 

 

1,256

 

 

$

46.65

 

 

 

7.01

 

Exercisable, end of the period

 

 

733

 

 

$

62.55

 

 

 

5.54

 

Vested and expected to vest, end of period

 

 

1,162

 

 

$

48.30

 

 

 

6.84

 

 

As of March 31, 2024, there was $1.12 million of total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over an estimated weighted-average period of 1.73 years. As of March 31, 2024, total compensation cost not yet recognized related to grants under the ESPP was approximately $7 thousand, which is expected to be recognized over four months.

The following table presents the weighted average assumptions that were used in the Black‑Scholes option pricing model to determine the fair value of stock options granted during the period, and the resulting weighted-average fair values:

 

 

 

Three months ended
March 31, 2024

 

 

Three months ended
March 31, 2023

 

Risk-free interest rate

 

 

4.07

%

 

 

3.41

%

Expected dividend yield

 

 

 

 

 

 

Expected volatility

 

 

83.1

%

 

 

80.3

%

Expected life of options (years)

 

5 years

 

 

5 years

 

Grant date fair value

 

$

1.36

 

 

$

6.60

 

 

The Company uses historical data to estimate the expected dividend yield and expected volatility of its Common Shares in determining the fair value of stock options. The expected life of the options represents the estimated length of time the options are expected to remain outstanding.

The following table presents the vesting terms of options granted in the period:

 

 

 

Three months ended
March 31, 2024

 

 

Three months ended
March 31, 2023

 

 

 

Number of options
(in thousands)

 

 

Number of options
(in thousands)

 

3-year vesting (50%-25%-25%)

 

 

20

 

 

 

48

 

4-year vesting (50%-16 2/3%-16 2/3%-16 2/3%)

 

 

388

 

 

 

167

 

Total stock options granted in the period

 

 

408

 

 

 

215

 

 

The Company has a stock incentive plan (SIP) pursuant to which the Board may grant stock-based awards comprised of restricted stock units or dividend equivalents to employees, officers, consultants, independent contractors, advisors and non-employee directors of the Company. Each restricted unit is automatically redeemed for one common share of the Company upon vesting. During the three-month period ended March 31, 2024, the Company granted nil (March 31, 2023 - 38,000) restricted stock units ("RSUs") with immediate vesting and an exercise price of $9.90. On February 6, 2023, all of these RSUs were redeemed for 38,000 Common Shares. The following table presents the vesting and redemption of the RSUs granted in the three months ended March 31, 2024 and 2023.

 

 

Three months ended
March 31, 2024

 

Three months ended
March 31, 2023

 

 

Number of options
(in thousands)

 

Weighted average grant date fair value

 

Number of options
(in thousands)

 

Weighted average grant date fair value

 

Outstanding, beginning of period

 

 

$

 

 

 

$

 

Granted

 

 

 

 

 

38

 

 

9.90

 

Vested and redeemed

 

 

 

 

 

(38

)

 

9.90

 

Outstanding, ending of period

 

 

$

 

 

 

$

 

 

b.
Share-based payment expense

The Company recorded share-based payment expense related to stock options and RSUs as follows:

 

 

 

Three months ended
March 31,

 

 

 

2024

 

 

2023

 

Research and development

 

$

328

 

 

$

652

 

General and administrative

 

 

481

 

 

 

1,222

 

 

 

$

809

 

 

$

1,874